Form 4: Adial Pharmaceuticals CEO Acquires 350,000 Stock Options

Adial Pharmaceuticals' CEO, Cary J. Claiborne, was granted 350,000 stock options on December 5, 2024, which vest monthly over 36 months.

Summary

• Cary J. Claiborne, the CEO of Adial Pharmaceuticals, was granted 350,000 stock options on December 5, 2024.
• These options have an exercise price of $1.15 per share.
• The options vest pro rata on a monthly basis over 36 months, starting December 5, 2024.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotechnology and pharmaceutical sectors.
• The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment and performance.
• The exercise price of $1.15 is specific to Adial Pharmaceuticals and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, executive compensation, insider trading, Adial Pharmaceuticals, ADIL, Cary J. Claiborne